There have been many anecdotal reports and case reports in the literature of these adverse events in patients using these medications for weight loss
Many patients continue making progress after reviewing their treatment plan, improving nutrition, increasing protein intake, adding resistance training, or adjusting medication under provider guidance
Dual Hormone Action Targets both GIP and GLP-1 receptors simultaneously
While mild to moderate bloating is a common and generally manageable side effect of semaglutide, certain symptoms warrant prompt medical evaluation
The brand-name experience (pre-filled pen, FDA approval, brand recognition) is worth $25 to most patients when the alternative is $179
The dose increases over time to move from a tolerability phase into a therapeutically active range